The overall objectives of this BETRNet Translational Research Center (TRC-F) are: 1) to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) 2) to increase the biological understanding of key observations made by our clinical researchers (familial aggregation of BE and EAC, restitution of squamous mucosa after ablation);3) to translate knowledge derived from genetic and physiologic research to solving clinical dilemmas in detection, prognosis, and therapy of BE in order to prevent EAC and improve the outcomes of EAC;4) to foster a transdisciplinary and translational research culture and to effectively expand and enhance scientific research focused on BE and EAC;5) to evaluate research and transdisciplinary programs and to continuously Improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this TRCF proposal is 1) to focus research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC;2) to explore the physiologic, transcriptional, and epigenetic factors that lead to durable ablation of BE;and 3) to translate discoveries into applications that improve familial screening, effective detection, molecular prognostication, and durable ablation of BE.
Esophageal adenocarcinoma (EAC) is a rapidly rising public health problem and its prognosis remains poor. Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma but it often goes undetected. The BETRNet TRC-F focuses on genetic, molecular, and physiologic studies that will develop better methods for detecting BE, predicting its progression to EAC, and eradicating BE that is at risk for developing EAC.
|Sanchis-Gomar, Fabian; Lucia, Alejandro; Yvert, Thomas et al. (2015) Physical inactivity and low fitness deserve more attention to alter cancer risk and prognosis. Cancer Prev Res (Phila) 8:105-10|
|Abrams, Julian A; Appelman, Henry D; Beer, David G et al. (2014) Barrett's Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. Gastroenterology 146:1586-90|
|Kaz, Andrew M; Grady, William M (2014) Epigenetic biomarkers in esophageal cancer. Cancer Lett 342:193-9|
|Alashkar, Bronia; Faulx, Ashley L; Hepner, Ashley et al. (2014) Development of a program to train physician extenders to perform transnasal esophagoscopy and screen for Barrett's esophagus. Clin Gastroenterol Hepatol 12:785-92|
|Berger, Nathan A (2014) Obesity and cancer pathogenesis. Ann N Y Acad Sci 1311:57-76|
|Chak, Amitabh; Alashkar, Bronia M; Isenberg, Gerard A et al. (2014) Comparative acceptability of transnasal esophagoscopy and esophageal capsule esophagoscopy: a randomized, controlled trial in veterans. Gastrointest Endosc 80:774-82|
|Wolf, W Asher; Dellon, Evan S; Shaheen, Nicholas J (2014) Esophageal diseases. Gastrointest Endosc 80:374-9|
|Garman, Katherine S; Owzar, Kouros; Hauser, Elizabeth R et al. (2013) MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer. Dig Dis Sci 58:3178-88|
|Greer, K B; Kresak, A; Bednarchik, B et al. (2013) Insulin/Insulin-Like Growth Factor-1 Pathway in Barrett's Carcinogenesis. Clin Transl Gastroenterol 4:e31|
|Orman, Eric S; Li, Nan; Shaheen, Nicholas J (2013) Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 11:1245-55|
Showing the most recent 10 out of 15 publications